Preventing early cardiovascular death in patients with familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Metabolic Disorders

Background:

• Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder.
• It leads to severely elevated total and LDL cholesterol levels.
• FH affects over 600,000 individuals in the US, causing premature cardiovascular disease.

Purpose of the Study:

• To review the screening, diagnosis, and management of Familial hypercholesterolemia.
• To highlight the importance of identifying and treating FH to prevent cardiovascular events.

Main Methods:

• Review of current literature on FH screening protocols.
• Analysis of pharmacologic (statins, lipid-lowering medications) and non-pharmacologic (LDL apheresis) treatment options.
• Discussion of diagnostic criteria and management guidelines for FH.

Main Results:

• FH is significantly underdiagnosed and undertreated despite its prevalence.
• Pharmacotherapy, particularly statins, is effective in managing FH.
• LDL apheresis serves as a vital non-pharmacologic option for non-responsive or intolerant patients.

Conclusions:

• Screening for FH is essential for early detection and intervention.
• Timely diagnosis and appropriate management, including drug therapy, can significantly reduce mortality.
• A comprehensive approach to FH management can save lives and prevent premature cardiovascular death.